Healthcare provider profile · identity verified

Robert S Eden, MD

Family Practice · ANNAPOLIS, MD · NPI 1902806409

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	224	86
Levothyroxine Sodium	Levothyroxine Sodium	206	68
Losartan Potassium	Losartan Potassium	186	80
Atorvastatin Calcium	Atorvastatin Calcium	175	71
Amlodipine Besylate	Amlodipine Besylate	172	84
Hydrochlorothiazide	Hydrochlorothiazide	170	70
Lisinopril	Lisinopril	157	58
Metoprolol Succinate	Metoprolol Succinate	136	57
Tamsulosin Hcl	Tamsulosin Hcl	115	42
Pravastatin Sodium	Pravastatin Sodium	114	38
Metformin Hcl	Metformin Hcl	110	40
Escitalopram Oxalate	Escitalopram Oxalate	81	33
Omeprazole	Omeprazole	75	28
Famotidine	Famotidine	72	27
Gabapentin	Gabapentin	68	31
Montelukast Sodium	Montelukast Sodium	66	27
Trazodone Hcl	Trazodone Hcl	65	27
Allopurinol	Allopurinol	58	22
Pantoprazole Sodium	Pantoprazole Sodium	57	23
Lorazepam	Lorazepam	53	21
Simvastatin	Simvastatin	52	20
Eliquis	Apixaban	51	20
Synthroid	Levothyroxine Sodium	48	15
Metformin Hcl Er	Metformin Hcl	45	15
Bupropion Xl	Bupropion Hcl	43	19
Furosemide	Furosemide	39	17
Zolpidem Tartrate	Zolpidem Tartrate	37	23
Albuterol Sulfate Hfa	Albuterol Sulfate	33	14
Buspirone Hcl	Buspirone Hcl	33	12
Clopidogrel	Clopidogrel Bisulfate	32	11
Fluticasone Propionate	Fluticasone Propionate	32	17
Januvia	Sitagliptin Phosphate	32	suppressed
Jardiance	Empagliflozin	31	suppressed
Potassium Chloride	Potassium Chloride	31	12
Venlafaxine Hcl Er	Venlafaxine Hcl	31	13
Ezetimibe	Ezetimibe	30	suppressed
Propranolol Hcl	Propranolol Hcl	30	12
Sertraline Hcl	Sertraline Hcl	30	12
Clonazepam	Clonazepam	27	suppressed
Alprazolam	Alprazolam	26	13
Valacyclovir	Valacyclovir Hcl	26	13
Ozempic	Semaglutide	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	11
Pregabalin	Pregabalin	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Atenolol	Atenolol	21	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Estradiol	Estradiol	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	21	suppressed
Carvedilol	Carvedilol	20	suppressed
Celecoxib	Celecoxib	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	14
Eszopiclone	Eszopiclone	18	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Diazepam	Diazepam	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Valsartan	Valsartan	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Finasteride	Finasteride	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error